Skip to content
WELCOME10 — 10% OFF YOUR FIRST ORDER  ·  FREE SHIPPING OVER $300 CAD  ·  COA ON EVERY ORDER

CJC-1295 (No DAC) FAQ: Your Questions Answered

The questions below are the ones that come up specifically about CJC-1295 (No DAC), rather than general peptide questions that apply to everything.

GHRH(1-29) tetra-substituted analogue (DAC-free)Hormonal & EndocrineMetabolic

Overview

People ask what no DAC means, whether it is the same as Modified GRF 1-29 (yes), why it pairs with Ipamorelin, and how it differs from Tesamorelin.

What CJC-1295 (No DAC) actually is

A trimmed, stabilised piece of the natural growth-hormone-releasing hormone that nudges the pituitary to release GH in short, natural pulses. Leaving off the DAC part keeps it short-acting, which is what researchers study it for. Often searched as Modified GRF 1-29.

Supplied for laboratory research use only — not for human or animal use.

Research-grade CJC-1295 (No DAC)

Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.

Technical detail below

CJC-1295 (No DAC) — common questions

What does no DAC mean?

The DAC (Drug Affinity Complex) version carries a group that binds albumin and stretches the half-life to days. Removing it leaves a short-acting molecule studied for producing tighter, more natural GH pulse patterns.

Is this the same as Modified GRF 1-29?

Yes. CJC-1295 without DAC and Modified GRF 1-29 refer to the same tetra-substituted GHRH(1-29) sequence.

Why is it studied with Ipamorelin?

They act through different receptors — GHRH receptor versus ghrelin receptor — so research designs often combine them to study complementary GH-release pathways.

Is it the same as Tesamorelin?

No. Both are DPP-4-resistant GHRH analogues, but Tesamorelin keeps the full 44-residue sequence with an N-terminal cap, while this molecule truncates to 29 residues and rebuilds stability through internal substitutions.

What CJC-1295 (No DAC) is studied for

Pulsatile GH release

Studied for prompting growth-hormone release in short, physiological pulses via the GHRH receptor.

DPP-4 resistance

The four substitutions are studied for extending the molecule beyond the minutes-long survival of native GHRH.

Complementary pairing

Frequently studied alongside ghrelin-receptor secretagogues such as Ipamorelin, which recruit a second GH-release pathway.

Summarizes published preclinical literature. Provided for research reference only; not a claim of efficacy or a description of human use.

More CJC-1295 (No DAC) reference

FAQ reference for other compounds

CJC-1295 (No DAC) overview CJC-1295 (No DAC) calculatorCJC-1295 (No DAC) product details

CJC-1295 (No DAC) is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.